LAB Stock Recent News

MEXICO CITY , June 13, 2024 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N.

SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSAXT system from Carterra®, a leading provider of high-throughput large and small molecule screening and characterization solutions. This instrument will enable Standard BioTools™ to further validate its SomaScan® Platform by measuring the kinetic properties of SOMAmer® Reagents and deliver precise information about protein binding and biomarker characterization to customers.

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that its management team will participate in the following investor conferences in the month of June: Jefferies Global Healthcare Conference on June 5th & 6th 2024.

Standard BioTools Inc. (NASDAQ:LAB ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants David Holmes - Investor Relations Michael Egholm - President and Chief Executive Officer Jeff Black - Chief Financial Officer Adam Taich - Chief Strategy Officer Conference Call Participants Matthew Stanton - Jefferies Daniel Brennan - TD Cowen Paul Knight - KeyBanc Capital Markets Operator Good day and welcome to the Standard BioTools Inc. First Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.

Standard BioTools Inc. (LAB) Q4 2023 Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that management will participate in the following investor conferences: TD Cowen's 44th Annual Healthcare Conference on Wednesday, March 6, 2024.

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of the market.

Standard BioTools Inc. (LAB) Q3 2023 Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will give a presentation with a moderated Q&A session at the Jefferies London Healthcare Conference on Wednesday, November 15 at 11:00 a.m. GMT.

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the close of the market.